{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:35:48Z","timestamp":1753882548888,"version":"3.41.2"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30874"],"award-info":[{"award-number":["2022JJ30874"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Thrombotic microangiopathy (TMA) is a rare side effect of interferon-beta (IFN-\u03b2) therapy. The clinical characteristics of IFN-\u03b2-induced TMA are unknown. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p> To explore the clinical characteristics of IFN-\u03b2-induced TMA and provide reference for the prevention of TMA. <\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p> Articles on IFN-\u03b2-induced TMA were collected by searching the literature in relevant Chinese and English databases from inception to 31 July 2023. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Data in the articles were extracted and analyzed retrospectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Forty-seven patients, with a median age of 41\u2009years (range 22, 66), were included in the analysis. The median time to the diagnosis of IFN-\u03b2-induced TMA was 8\u2009years (range 0.1\u201330) after administration. The main clinical symptoms were neurological symptoms (51.1%), hypertension (78.7%), dyspnea (19.1%), edema (19.1%), asthenia\/fatigue (19.1%), and digestive symptoms (17.0%). Most patients presented with hemolytic anemia (76.6%), thrombocytopenia (63.8%), and acute kidney injury (70.2%). All patients stopped IFN-\u03b2 and received plasma exchange therapy (53.2%), systemic steroids (46.8%), antihypertensive therapy (46.8%), eculizumab (12.8%), and rituximab (12.8%). Kidney damage was not completely reversible; 40.4% of patients achieved renal function and hematology remission, 27.7% developed chronic kidney disease, 25.5% developed end-stage renal disease, and 2.1% died. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> IFN-\u03b2-induced TMA is a rare but serious complication that can be life-threatening. It may occur after many years of IFN-\u03b2 therapy, and patients taking IFN-\u03b2 should be monitored for symptoms such as headache and hypertension. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562864231216634","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T06:36:35Z","timestamp":1702708595000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics, treatments, and outcomes of interferon-beta-induced thrombotic microangiopathy: a literature-based retrospective analysis"],"prefix":"10.1177","volume":"16","author":[{"given":"Chunjiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Chunjiang Wang is also affiliated to College of pharmacy, Changsha Medical University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Chunjiang Wang is also affiliated to College of pharmacy, Changsha Medical University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"Chunjiang Wang is also affiliated to College of pharmacy, Changsha Medical University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, Hunan 410013, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5519-2656","authenticated-orcid":false,"given":"Liping","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, Hunan 410013, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"bibr1-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13954"},{"key":"bibr2-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611335"},{"key":"bibr3-17562864231216634","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11470918"},{"key":"bibr4-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2016.06.001"},{"key":"bibr5-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1426462"},{"key":"bibr6-17562864231216634","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022020-00006"},{"key":"bibr7-17562864231216634","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512"},{"key":"bibr8-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-013-0401-7"},{"key":"bibr9-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-715987"},{"key":"bibr10-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200207000-00008"},{"key":"bibr11-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460220"},{"key":"bibr12-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-016-0220-7"},{"key":"bibr13-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.362"},{"key":"bibr14-17562864231216634","first-page":"2","volume":"14","author":"Laurence J","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"bibr15-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2013.09.027"},{"key":"bibr16-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000234"},{"key":"bibr17-17562864231216634","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599974"},{"key":"bibr18-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.246"},{"key":"bibr19-17562864231216634","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310"},{"key":"bibr20-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.10.009"},{"key":"bibr21-17562864231216634","first-page":"7063145","volume":"2018","author":"Atallah-Yunes SA","year":"2018","journal-title":"Case Rep Hematol"},{"key":"bibr22-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13714"},{"key":"bibr23-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12794"},{"key":"bibr24-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392202"},{"key":"bibr25-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1038\/35097008"},{"key":"bibr26-17562864231216634","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-10-200005160-00005"},{"key":"bibr27-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1765"},{"key":"bibr28-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1328894"},{"key":"bibr29-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02470-3"},{"key":"bibr30-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sft065"},{"key":"bibr31-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.04.005"},{"key":"bibr32-17562864231216634","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw143"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864231216634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864231216634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864231216634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:30:09Z","timestamp":1740803409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864231216634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":32,"alternative-id":["10.1177\/17562864231216634"],"URL":"https:\/\/doi.org\/10.1177\/17562864231216634","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"type":"print","value":"1756-2864"},{"type":"electronic","value":"1756-2864"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17562864231216634"}}